ASH 2018 | bb21217 results: a next-generation anti-BCMA CAR-T for R/R MM
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Promising results have been seen with bb21217, a next-generation anti-BCMA CAR T-cell therapy for the treatment of relapsed/refractory multiple myeloma (MM). Here, Nina Shah, MD, of the University of California, San Francisco, CA, discusses the preliminary safety and efficacy data from the ongoing CRB-402 trial (NCT03274219), which was presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up